Stay updated on Nivolumab Post-Surgery in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Post-Surgery in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Post-Surgery in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:33:54.000Z thumbnail image
  6. Check
    12 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to an Investigational Immuno-therapy Study of Nivolumab in Non-Small Cell Lung Cancer participants with minimal residual disease after surgery.
    Difference
    0.2%
    Check dated 2024-06-06T14:39:57.000Z thumbnail image
  7. Check
    26 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the health conditions and prior treatments required for participants. The new criteria include suspected or confirmed Stage IIA to IIIB NSCLC, eligibility for complete resection, and minimal residual disease detected by ctDNA.
    Difference
    21%
    Check dated 2024-05-22T21:26:55.000Z thumbnail image
  8. Check
    48 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:50:54.000Z thumbnail image

Stay in the know with updates to Nivolumab Post-Surgery in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Post-Surgery in NSCLC Clinical Trial page.